Receptos +36.7% AH; RPC1063 hits primary endpoint

|By:, SA News Editor

Receptos' (RCPT) RPC1063 multiple sclerosis drug met its primary endpoint (reduction in MRI brain lesion activity) during Phase 2 trials.

The company adds its ongoing Phase 3 trial "has been designed to confirm and extend [Phase 2] results." Phase 2 results for the use of RPC1063 in treating ulcerative colitis are expected in Q4.